Get the Stockscreener App
43.83
0.00%
0.00
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $43.83, with a volume of 10.10M.
It is up +0.00% in the last 24 hours and down -0.75% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$43.83
Open:
$43.93
24h Volume:
10.10M
Relative Volume:
0.73
Market Cap:
$89.21B
Revenue:
$47.70B
Net Income/Loss:
$5.07B
P/E Ratio:
17.68
EPS:
2.4784
Net Cash Flow:
$14.58B
1W Performance:
+0.46%
1M Performance:
-0.75%
6M Performance:
-9.98%
1Y Performance:
-17.18%
1-Day Range:
$43.58
$43.94
1-Week Range:
$43.34
$45.23
52-Week Range:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
43.83 | 89.21B | 47.70B | 5.07B | 14.58B | 2.4784 |
|
LLY
Lilly Eli Co
|
825.45 | 736.03B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.40 | 463.72B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
227.99 | 403.22B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.36 | 254.84B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.49 | 217.76B | 63.43B | 16.42B | 14.72B | 6.4861 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 (BMYMP.US) is scheduled to release its earnings report before the market opens on October 30. - 富途牛牛
Applying chart zones and confluence areas to Bristol Myers Squibb CompanyJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - The Globe and Mail
Is Bristol Myers Squibb Company stock resilient to inflationPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy - Yahoo Finance
Risk adjusted return profile for Bristol Myers Squibb Company Equity Right analyzedPortfolio Profit Report & AI Enhanced Trading Alerts - newser.com
Forecasting Bristol Myers Squibb Company Equity Right price range with options dataMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
Will Bristol Myers Squibb Company stock deliver better than expected guidanceTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
Can Bristol-Myers Squibb’s Innovation Push Reverse Its Stock Slide? - AD HOC NEWS
Is Bristol Myers Squibb Company (BRM) stock cheap vs fundamentalsJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Bristol-Myers $450M Payment Dispute Heads To Arbitration - Law360
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks - The Motley Fool
Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know - Yahoo Finance
Trend analysis for Bristol Myers Squibb Company this week2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
The Play On Bristol-Myers Squibb (NYSE:BMY) - Seeking Alpha
Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock - Insider Monkey
Small Cell Lung Cancer Market Research 2025-2035: Growth Driven by Advancements in Novel Therapies, Including Immunotherapies, Targeted Therapies, and Combination Treatments - GlobeNewswire Inc.
How high can Bristol Myers Squibb Company stock goJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - newser.com
Will Bristol Myers Squibb Company Celegne Contingent stock benefit from Fed rate cuts2025 Technical Overview & High Accuracy Swing Entry Alerts - newser.com
Bristol-Myers’ $450 Million Earnout Pay Fight Sent to Arbitrator - Bloomberg Law News
US CBO says orphan drug exemption could add $6 billion to cost of Trump's 'Big Beautiful Bill' - Reuters
Can Bristol-Myers Squibb Stock Recover After Steep Decline? - AD HOC NEWS
Bristol-Myers Squibb (BMY) Investor Outlook: Navigating a 21.59% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Can Bristol Myers Squibb Company stock hit record highs againMarket Performance Recap & Expert Verified Movement Alerts - newser.com
Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug - GuruFocus
Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Resul - GuruFocus
Bristol Myers Squibb, SystImmune report data from lung cancer trial - Seeking Alpha
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 - Yahoo Finance
Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India - Yahoo Finance
Is Bristol Myers Squibb Company Equity Right building a consolidation baseMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com
Does Bristol Myers Stock Offer Value as AI Data-Sharing Alliance Makes Headlines? - simplywall.st
insitro and Bristol Myers Squibb (BMY) Advance ALS Research with New AI-Powered Collaboration - Yahoo Finance
Bristol Myers Squibb Launches Kopozgo (Mavacamten) In IndiaStatement - TradingView
What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Deck Bio and ReTrax Therapeutics Awarded 2025 Bristol Myers Squibb Golden Tickets - Yahoo Finance
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Orbital Therapeutics Deal - Insider Monkey
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com Australia
BMY Collaboration Advances ALS Treatment Development - GuruFocus
$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan
Bristol Myers Squibb describes new FAK degradation inducers - BioWorld MedTech
11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review
What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st
Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma
What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl
Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend - Insider Monkey
Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.28%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):